Prevalence of seropositive toxoplasma cases in association with the frequency of abortion in sheep and goat

Toxoplasmosis are a serious public-health problem inhuman and animals especially in developing countries, it appear approximately thirty percent from all cases and have higher level of morbidity .At every stage of life the Toxoplasma gondii infections are a significant cause .The epidemiology and handling of this condition are various in the developing world, where infectious agents became predominate .This study was proceed during the period from March 2017 to August 2017 to detect Toxoplasma gondii in sheep and goat serum by characterize them using two assays Latex agglutination test and IgG and IgM Toxoplasmosis ELISA kits.A total of 74 sera samples were collected from sheep and goat from different ages ranged 6 month to 2.5 years old were achieved in different reign in AL- Najaf city / Iraq ,they suffered from endemic abortion and still birth. The overall prevalence of Toxoplasma gondii in were32(62%),18(75%) by Latex agglutination test for sheep and goat, respectively, with non-significant variation (P>0.05) between the two them ,The serum are arranged as follows in a total of 23 (71.8%) and 9 (28.2%)abortion and still birth of sheep ,respectively, and17(94.4%) 1(5.6%) aborted and still birth of goat ,respectively, with significant differences (P≤0.05) between the two them. Out of 32 serum positive of Toxoplasmosis in sheep by using Latex agglutination test,  there were 23(71,9%) and 11(43,4%) positive serum by using IgG and IgM ELISA kits, respectively, On the other hand out of 18 toxoplasmosis parasite in goat have positive result in Latex agglutination test, there were 11(61,1%) and 6(33,3%) by using IgG and IgM ELISA kits, respectively, our study was accelerated due to endemic clinical abortion and instill birth for sheep and goat and narrowing functional range of molecular assays by time consumption, in this regard the aim of our study used two functional assay  diagnosis Latex agglutination assay and ELISA techniques with  increase the accuracy for the detection of the Toxoplasmosis in sheep and goat

The Trail Pheromone of the Venomous Samsum Ant, Pachycondyla sennaarensis

Ant species use branching networks of pheromone trails for orientation between nest and resources. The current study demonstrated that workers of the venomous samsum ant, Pachycondyla sennaarensis (Mayr) (Hymenoptera: Formicidae: Ponerinae), employ recruitment trail pheromones discharged from the Dufour's gland. Secretions of other abdomen complex glands, as well as hindgut gland secretions, did not evoke trail following. The optimum concentration of trail pheromone was found to be 0.1 gland equivalent/40 cm trail. This concentration demonstrated effective longevity for about one hour. This study also showed that P. sennaarensis and Tapinoma simrothi each respond to the trail pheromones of the other species as well as their own

REVIEW-STRATEGIES INDICATORS OF TREATMENT OF GINGIVAL RECESSION

Globally, gingival recession is extremely widespread. It raises the risk for root caries and can impair patient comfort, function, and appearance. We searched electronic databases for all pertinent research published up until the middle of 2022. Additionally, progressive gingival recession raises the likelihood of tooth loss due to clinical attachment loss. Although reducing the causes of gingival recession reduces its incidence and severity, it can be difficult to implement realistic management and preventative techniques in a clinical context. Developing action plans for relevant therapies begins with identifying susceptible patients and evaluating them for the presence of modifiable risk exposures

Assessment of Uptake, Accumulation and Degradation of Paracetamol in Spinach (Spinacia oleracea L.) under Controlled Laboratory Conditions

The occurrence and persistence of pharmaceuticals in the food chain, particularly edible crops, can adversely affect human and environmental health. In this study, the impacts of the absorption, translocation, accumulation, and degradation of paracetamol in different organs of the leafy vegetable crop spinach (Spinacia oleracea) were assessed under controlled laboratory conditions. Spinach plants were exposed to 50 mg/L, 100 mg/L, and 200 mg/L paracetamol in 20% Hoagland solution at the vegetative phase in a hydroponic system. Exposed plants exhibited pronounced phytotoxic effects during the eight days trial period, with highly significant reductions seen in the plants’ morphological parameters. The increasing paracetamol stress levels adversely affected the plants’ photosynthetic machinery, altering the chlorophyll fluorescence parameters (Fv/Fm and PSII), photosynthetic pigments (Chl a, Chl b and carotenoid contents), and composition of essential nutrients and elements. The LC-MS results indicated that the spinach organs receiving various paracetamol levels on day four exhibited significant uptake and translocation of the drug from roots to aerial parts, while degradation of the drug was observed after eight days. The VITEK® 2 system identified several bacterial strains (e.g., members of Burkhulderia, Sphingomonas, Pseudomonas, Staphylococcus, Stenotrophomonas and Kocuria) isolated from spinach shoots and roots. These microbes have the potential to biodegrade paracetamol and other organic micro-pollutants. Our findings provide novel insights to mitigate the risks associated with pharmaceutical pollution in the environment and explore the bioremediation potential of edible crops and their associated microbial consortium to remove these pollutants effectively

Comparison of a modified pediatric protocol versus a hyper-CVAD protocol in adolescents and young adults with Philadelphia-negative acute lymphoblastic leukemia: a multicenter retrospective analysis

Background The outcomes of Pediatric acute lymphoblastic leukemia (ALL) have improved dramatically whereas outcomes for ALL amongst adolescents and young adults (AYA) have lagged behind. The introduction of pediatric-like regimens to manage adult ALL has shown promising outcomes across several analyses. Materials and Methods In this analysis, we aimed to retrospectively compare the differences in outcomes among patients aged 14-40 years with Philadelphia-negative ALL treated with a Hyper-CVAD protocol versus a modified pediatric protocol. Results A total of 103 patients were identified with 58 (56.3%) in the modified ABFM group and 45 (43.7%) in the hyper-CVAD group. The median duration of follow-up for the cohort was 39 months (range 1-93). There were significantly lower rates of MRD persistence after consolidation (10.3% vs. 26.7%, P=0.031) and transplantation (15.5% vs. 46.6%, P<0.001) in the modified ABFM group. 5-year OS rates (83.9% vs. 65.3%, P=0.036) and DFS rates (67.4% vs. 44%, P=0.014) were higher in the modified ABFM groups. The incidence of grade 3 and 4 hepatotoxicity (24.1% vs. 13.3%, P<0.001) and osteonecrosis (20.6% vs. 2.2%, P=0.005) were higher in the modified ABFM group. Conclusion Our analysis demonstrates that the use of a pediatric modified ABFM protocol demonstrated superior outcomes compared to the hyper-CVAD regimen in the treatment of Philadelphia-negative ALL amongst AYA patients. However, the modified ABFM protocol was associated with an increased risk of certain toxicities including high grade liver toxicity and osteonecrosis. Data Availability Statement The original contributions presented in this study are included in the article/supplementary material, further inquiries can be directed to the corresponding author

Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021

Background Future trends in disease burden and drivers of health are of great interest to policy makers and the public at large. This information can be used for policy and long-term health investment, planning, and prioritisation. We have expanded and improved upon previous forecasts produced as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) and provide a reference forecast (the most likely future), and alternative scenarios assessing disease burden trajectories if selected sets of risk factors were eliminated from current levels by 2050. Methods Using forecasts of major drivers of health such as the Socio-demographic Index (SDI; a composite measure of lag-distributed income per capita, mean years of education, and total fertility under 25 years of age) and the full set of risk factor exposures captured by GBD, we provide cause-specific forecasts of mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) by age and sex from 2022 to 2050 for 204 countries and territories, 21 GBD regions, seven super-regions, and the world. All analyses were done at the cause-specific level so that only risk factors deemed causal by the GBD comparative risk assessment influenced future trajectories of mortality for each disease. Cause-specific mortality was modelled using mixed-effects models with SDI and time as the main covariates, and the combined impact of causal risk factors as an offset in the model. At the all-cause mortality level, we captured unexplained variation by modelling residuals with an autoregressive integrated moving average model with drift attenuation. These all-cause forecasts constrained the cause-specific forecasts at successively deeper levels of the GBD cause hierarchy using cascading mortality models, thus ensuring a robust estimate of cause-specific mortality. For non-fatal measures (eg, low back pain), incidence and prevalence were forecasted from mixed-effects models with SDI as the main covariate, and YLDs were computed from the resulting prevalence forecasts and average disability weights from GBD. Alternative future scenarios were constructed by replacing appropriate reference trajectories for risk factors with hypothetical trajectories of gradual elimination of risk factor exposure from current levels to 2050. The scenarios were constructed from various sets of risk factors: environmental risks (Safer Environment scenario), risks associated with communicable, maternal, neonatal, and nutritional diseases (CMNNs; Improved Childhood Nutrition and Vaccination scenario), risks associated with major non-communicable diseases (NCDs; Improved Behavioural and Metabolic Risks scenario), and the combined effects of these three scenarios. Using the Shared Socioeconomic Pathways climate scenarios SSP2-4.5 as reference and SSP1-1.9 as an optimistic alternative in the Safer Environment scenario, we accounted for climate change impact on health by using the most recent Intergovernmental Panel on Climate Change temperature forecasts and published trajectories of ambient air pollution for the same two scenarios. Life expectancy and healthy life expectancy were computed using standard methods. The forecasting framework includes computing the age-sex-specific future population for each location and separately for each scenario. 95% uncertainty intervals (UIs) for each individual future estimate were derived from the 2·5th and 97·5th percentiles of distributions generated from propagating 500 draws through the multistage computational pipeline. Findings In the reference scenario forecast, global and super-regional life expectancy increased from 2022 to 2050, but improvement was at a slower pace than in the three decades preceding the COVID-19 pandemic (beginning in 2020). Gains in future life expectancy were forecasted to be greatest in super-regions with comparatively low life expectancies (such as sub-Saharan Africa) compared with super-regions with higher life expectancies (such as the high-income super-region), leading to a trend towards convergence in life expectancy across locations between now and 2050. At the super-region level, forecasted healthy life expectancy patterns were similar to those of life expectancies. Forecasts for the reference scenario found that health will improve in the coming decades, with all-cause age-standardised DALY rates decreasing in every GBD super-region. The total DALY burden measured in counts, however, will increase in every super-region, largely a function of population ageing and growth. We also forecasted that both DALY counts and age-standardised DALY rates will continue to shift from CMNNs to NCDs, with the most pronounced shifts occurring in sub-Saharan Africa (60·1% [95% UI 56·8–63·1] of DALYs were from CMNNs in 2022 compared with 35·8% [31·0–45·0] in 2050) and south Asia (31·7% [29·2–34·1] to 15·5% [13·7–17·5]). This shift is reflected in the leading global causes of DALYs, with the top four causes in 2050 being ischaemic heart disease, stroke, diabetes, and chronic obstructive pulmonary disease, compared with 2022, with ischaemic heart disease, neonatal disorders, stroke, and lower respiratory infections at the top. The global proportion of DALYs due to YLDs likewise increased from 33·8% (27·4–40·3) to 41·1% (33·9–48·1) from 2022 to 2050, demonstrating an important shift in overall disease burden towards morbidity and away from premature death. The largest shift of this kind was forecasted for sub-Saharan Africa, from 20·1% (15·6–25·3) of DALYs due to YLDs in 2022 to 35·6% (26·5–43·0) in 2050. In the assessment of alternative future scenarios, the combined effects of the scenarios (Safer Environment, Improved Childhood Nutrition and Vaccination, and Improved Behavioural and Metabolic Risks scenarios) demonstrated an important decrease in the global burden of DALYs in 2050 of 15·4% (13·5–17·5) compared with the reference scenario, with decreases across super-regions ranging from 10·4% (9·7–11·3) in the high-income super-region to 23·9% (20·7–27·3) in north Africa and the Middle East. The Safer Environment scenario had its largest decrease in sub-Saharan Africa (5·2% [3·5–6·8]), the Improved Behavioural and Metabolic Risks scenario in north Africa and the Middle East (23·2% [20·2–26·5]), and the Improved Nutrition and Vaccination scenario in sub-Saharan Africa (2·0% [–0·6 to 3·6]). Interpretation Globally, life expectancy and age-standardised disease burden were forecasted to improve between 2022 and 2050, with the majority of the burden continuing to shift from CMNNs to NCDs. That said, continued progress on reducing the CMNN disease burden will be dependent on maintaining investment in and policy emphasis on CMNN disease prevention and treatment. Mostly due to growth and ageing of populations, the number of deaths and DALYs due to all causes combined will generally increase. By constructing alternative future scenarios wherein certain risk exposures are eliminated by 2050, we have shown that opportunities exist to substantially improve health outcomes in the future through concerted efforts to prevent exposure to well established risk factors and to expand access to key health interventions